Cipla USA Receives USFDA Approval for Generic Nintedanib for Pulmonary Fibrosis Treatment

Cipla USA has received approval from the US Food and Drug Administration (USFDA) for its generic version of nintedanib, a drug used in the treatment of pulmonary fibrosis. The approval marks a significant regulatory milestone for Cipla’s respiratory portfolio in the United States market.

Expanding Access in Rare Respiratory Care

The approval of generic nintedanib is expected to improve patient access to an essential therapy used in managing idiopathic pulmonary fibrosis and other chronic lung conditions. By introducing a more affordable alternative, Cipla aims to address unmet needs in a high-cost specialty treatment segment.

Strengthening Cipla’s US Generics Pipeline

This development reinforces Cipla USA’s strategic focus on expanding its complex generics portfolio in the regulated US market. The approval further strengthens the company’s presence in respiratory therapeutics, a key growth area within its global pharmaceutical strategy.